Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
4.100
-0.200 (-4.65%)
At close: May 29, 2026, 4:00 PM EDT
4.101
+0.001 (0.02%)
After-hours: May 29, 2026, 7:58 PM EDT
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $71.43M in the quarter ending March 31, 2026, with 44.82% growth. This brings the company's revenue in the last twelve months to $285.61M, up 34.29% year-over-year. In the year 2025, Iovance Biotherapeutics had annual revenue of $263.50M with 60.60% growth.
Revenue (ttm)
$285.61M
Revenue Growth
+34.29%
P/S Ratio
6.41
Revenue / Employee
$292,931
Employees
975
Market Cap
1.83B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 263.50M | 99.43M | 60.60% |
| Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
| Dec 31, 2023 | 1.19M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.20B |
| Aurinia Pharmaceuticals | 298.30M |
| Zymeworks | 81.26M |
| Viridian Therapeutics | 70.92M |
| Intellia Therapeutics | 66.09M |
| Mesoblast | 65.38M |
| Ocular Therapeutix | 52.04M |
| Stoke Therapeutics | 32.08M |
IOVA News
- 8 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 9 days ago - Iovance Biotherapeutics to Present at Upcoming Conference - GlobeNewsWire
- 23 days ago - Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan - TheFly
- 23 days ago - Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c) - TheFly
- 23 days ago - Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M - TheFly
- 23 days ago - Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M - TheFly
- 23 days ago - Iovance Biotherapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 23 days ago - Iovance Biotherapeutics Earnings release: Q1 2026 - Filings